Biotech · Private company · San Diego, CA, US
Vaxiion Therapeutics
Track this companyFree. Adds Vaxiion Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- Nivolumab or pembrolizumabPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- VAX014Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- VAX014Phase 1 · Urothelial Carcinoma of the Urinary BladderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid TumorsPHASE1 · RECRUITING · started Nov 2, 2023ClinicalTrials.gov NCT05901285 · fetched Nov 12, 2026
- A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder CancerPHASE1 · COMPLETED · started May 10, 2019ClinicalTrials.gov NCT03854721 · fetched Nov 12, 2026
NIH awards1
- Preclinical development of VAX024 - a novel targeted combination STING agonist/oncolytic agentFiscal year 2025 · $306.3KNIH RePORTER 1R43CA298595-01 · fetched Nov 12, 2026